An experimental Allergan pill meant to help reduce the frequency of migraines met the main goals of a key study, bolstering its chances of eventually being in the mix with a new wave of injectable migraine-preventing therapies.
The results announced Monday for the Allergan (NYSE: AGN) drug, atogepant, come a month after Amgen (NASDAQ: AMGN) won FDA approval of erenumab (Aimovig), the first marketed drug in this new class of migraine treatments. But Allergan’s results are particularly notable because atogepant is a pill. Amgen’s migraine drug, and several others still awaiting an FDA decision, are administered with a… Read more »
UNDERWRITERS AND PARTNERS